Subcribe RSS Feed
Houston, TX: Postdoctoral Position in Cancer Parmacogenetics, University of Texas M.D. Anderson Cancer Center
Postdoctoral Position in Cancer Parmacogenetics
Employer: The University of Texas M.D. Anderson Cancer Center (Others)
Location: Houston, TX 77030
Category: Postdoc/Graduate Assistant position of:
Cancer Biology/Oncology
Genetics & Genomics
Posted: Mar. 08, 2008
Job Type: Full-time
Deadline: Open until filled
Description & Requirement
A postdoctoral position in the field of cancer pharmacogenetics is available immediately in Dr. Xifeng Wu’s lab at The University of Texas M.D. Anderson Cancer Center to identify clinically relevant biomarkers to predict treatment outcomes of various types of cancer therapy such as radiotherapy, chemotherapy, and molecularly targeted therapy.
Cancer pharmacogenetics utilizes genetic variation in the human genome and other biological and pathological markers as surrogates of treatment outcome in order to achieve tailored therapy based on specific genetic profile of each cancer patient. Along with the completion of the Human Genome Sequencing Project, the International HapMap Project, and the ongoing Cancer Genome Sequencing Project, the field of cancer pharmacogenetics is expanding rapidly. Successful applicant of this National Cancer Institute (NCI)-funded position of postdoctoral fellow will have great opportunities to collaborate with an interdisciplinary team of biologists, epidemiologists, statisticians, and clinicians, and to develop multidisciplinary knowledge and techniques in molecular and cellular biology, epidemiology, statistics, genetics, genomics, and cancer medicine. The large collection of biospecimens from a number of cancer types in our laboratory will greatly facilitate the realization of promising novel ideas in the fields of cancer risk assessment, prevention, early detection, and individualized intervention.
For a brief review of cancer pharmacogenetics:
• Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2001 Nov;1(2):99-108
For examples of the application of pharmacogenetics in individualized cancer therapy:
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39.
• Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004 Aug 20;305(5687):1163-7.
For selected recent publications (from a total of >100) on cancer pharmacogenetics and risk assessment in our lab:
• Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006 Aug 10;24(23):3789-98
• Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006 Mar;78(3):464-79.
• The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. Pharmacogenomics. 2005 Sep;6(6):575-84.
• Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005 Aug 20;23(24):5746-56.
• An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Cancer Res. 2004 Mar 15;64(6):2251-7.
• Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst. 2003 Aug 20;95(16):1211-8.
We seek highly motivated individuals who have a Ph.D. and/or M.D. degree with less than 2 years of postdoctoral experience in biochemistry, molecular biology, cellular biology, genetics, or related fields. Applications, including a resume/curriculum vitae, contact information for three references, and a brief summary of past accomplishments should be sent by regular mail or email to: Xifeng Wu, M.D., Ph.D., Department of Epidemiology, Division of Cancer Prevention and Populational Science, The University of Texas M.D. Anderson Cancer Center, 1155 Pressler Blvd. Box 1340, Houston, TX, 77030. Email: xwu@mdanderson.org.
Application
Xifeng Wu, M.D., Ph.D.
Department of Epidemiology
Division of Cancer Prevention and Populational Science
The University of Texas M.D. Anderson Cancer Center
1155 Pressler Blvd. Box 1340
Houston, TX, 77030
Email: xwu@mdanderson.org
Employer: The University of Texas M.D. Anderson Cancer Center (Others)
Location: Houston, TX 77030
Category: Postdoc/Graduate Assistant position of:
Cancer Biology/Oncology
Genetics & Genomics
Posted: Mar. 08, 2008
Job Type: Full-time
Deadline: Open until filled
Description & Requirement
A postdoctoral position in the field of cancer pharmacogenetics is available immediately in Dr. Xifeng Wu’s lab at The University of Texas M.D. Anderson Cancer Center to identify clinically relevant biomarkers to predict treatment outcomes of various types of cancer therapy such as radiotherapy, chemotherapy, and molecularly targeted therapy.
Cancer pharmacogenetics utilizes genetic variation in the human genome and other biological and pathological markers as surrogates of treatment outcome in order to achieve tailored therapy based on specific genetic profile of each cancer patient. Along with the completion of the Human Genome Sequencing Project, the International HapMap Project, and the ongoing Cancer Genome Sequencing Project, the field of cancer pharmacogenetics is expanding rapidly. Successful applicant of this National Cancer Institute (NCI)-funded position of postdoctoral fellow will have great opportunities to collaborate with an interdisciplinary team of biologists, epidemiologists, statisticians, and clinicians, and to develop multidisciplinary knowledge and techniques in molecular and cellular biology, epidemiology, statistics, genetics, genomics, and cancer medicine. The large collection of biospecimens from a number of cancer types in our laboratory will greatly facilitate the realization of promising novel ideas in the fields of cancer risk assessment, prevention, early detection, and individualized intervention.
For a brief review of cancer pharmacogenetics:
• Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2001 Nov;1(2):99-108
For examples of the application of pharmacogenetics in individualized cancer therapy:
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39.
• Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004 Aug 20;305(5687):1163-7.
For selected recent publications (from a total of >100) on cancer pharmacogenetics and risk assessment in our lab:
• Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006 Aug 10;24(23):3789-98
• Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006 Mar;78(3):464-79.
• The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. Pharmacogenomics. 2005 Sep;6(6):575-84.
• Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005 Aug 20;23(24):5746-56.
• An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Cancer Res. 2004 Mar 15;64(6):2251-7.
• Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst. 2003 Aug 20;95(16):1211-8.
We seek highly motivated individuals who have a Ph.D. and/or M.D. degree with less than 2 years of postdoctoral experience in biochemistry, molecular biology, cellular biology, genetics, or related fields. Applications, including a resume/curriculum vitae, contact information for three references, and a brief summary of past accomplishments should be sent by regular mail or email to: Xifeng Wu, M.D., Ph.D., Department of Epidemiology, Division of Cancer Prevention and Populational Science, The University of Texas M.D. Anderson Cancer Center, 1155 Pressler Blvd. Box 1340, Houston, TX, 77030. Email: xwu@mdanderson.org.
Application
Xifeng Wu, M.D., Ph.D.
Department of Epidemiology
Division of Cancer Prevention and Populational Science
The University of Texas M.D. Anderson Cancer Center
1155 Pressler Blvd. Box 1340
Houston, TX, 77030
Email: xwu@mdanderson.org
posted by Editor @ 3/19/2008
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home
Support the Fellowship Board